Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: -1.00 (-2.15%)
Spread: 1.00 (2.222%)
Open: 46.50
High: 45.50
Low: 45.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony

Mon, 10th Jan 2022 12:16

(Alliance News) - Stock prices in London were lower at midday on Monday as investors prepare for the prospect of more aggressive monetary policy from the US Federal Reserve.

The FTSE 100 index was down 12.45 points, or 0.2%, at 7,472.87. The mid-cap FTSE 250 index was down 60.97 points, or 0.3%, at 23,292.28. The AIM All-Share index was down 4.15 points, or 0.4%, at 1,183.19.

The Cboe UK 100 index was down 0.1% at 741.04. The Cboe 250 was down 0.2% at 20,778.02, but the Cboe Small Companies was up 0.1% at 15,593.25.

In Paris, the CAC 40 stock index was down 0.2%, while the DAX 40 in Frankfurt was 0.3% lower.

New York was pointed to a flat-to-lower open following a lower close on Friday with equity markets seeing an up-and-down start to 2022.

Dow Jones Industrial Average was called marginally higher, the S&P 500 down 0.5%, and the Nasdaq Composite down 1.3% based on futures trading.

Key data points this week will be consumer price index readings from the US and China on Wednesday, as the global economy contends with higher energy costs, supply chain blockages, and the fast-spreading Omicron variant of Covid-19.

The Fed faces a tough balancing act of having to adjust monetary policy to rein in prices while at the same time avoid hindering the economic recovery.

The US central bank has already started tapering its vast bond-buying programme, put in place at the start of the pandemic, and has signalled it could start lifting interest rates from record lows from March, with some observers predicting multiple hikes this year.

Fed Chair Jerome Powell will testify before the Senate Banking Committee on Tuesday.

Analysts at ActivTrades said: "Market volatility continues to grow almost everywhere for the beginning of the new year as lingering uncertainties keep pressure on market sentiment. Investors are still digesting the sooner-than-expected hawkish pivot from the Fed, with the first rate hike now anticipated in the first quarter (March) as well as further rises expected later in the year. The huge hit and impact of the Omicron strain on economies combined with the prospect of withdrawn liquidity from central banks is denting investors' appetite for riskier assets in the short-term.

"Traders are likely to wait for new major market drivers before pushing stock prices in new directions. All eyes will remain on monetary policy this week with a new batch of comments from major Fed speakers alongside the crucial US inflation report on Wednesday."

In the FTSE 100, housebuilders were the worst performers after the UK government announced plans to resolve the flammable cladding crisis.

Persimmon was down 4.7%, Barratt Developments down 3.6%, Taylor Wimpey down 2.5%, and Berkeley Group down 2.5%. Midcap builders Redrow, Bellway and Countryside were off 3.9%, 3.3% and 3.1% respectively.

Developers in the UK must agree a GBP4 billion plan to fix dangerous cladding on low-rise flats by early March or risk new laws forcing them to act, Housing Secretary Michael Gove has said.

The Cabinet minister threatened that he is "prepared to take all steps necessary" to fix the "broken system" in a letter to the industry ahead of detailing the plans on Monday. Potential action also includes restricting access to government funding and future procurements, the use of planning powers, and pursuing firms through the courts.

The proposals to alleviate the scandal that has trapped leaseholders in unsafe and unsellable homes come more than four years after the Grenfell Tower fire in June 2017, in which 72 people were killed. Leaseholders in buildings between 11 metres and 18m tall will no longer have to take out loans to cover the costs of remediation work despite no new money coming from the Treasury.

Instead, Gove told developers to agree to start contributing this year to cover the "full outstanding cost", which he estimates to be GBP4 billion.

"Many flat owners have been left with onerous costs for replacing flammable cladding and the latest reports on who will foot the bill should come as no surprise to the sector in that context," said AJ Bell's Russ Mould. "The housebuilders have benefited from generous incentives, such as Help to Buy and the mortgage guarantee scheme, in recent years. However, state support is not a one-way street, and the sector needs to do its bit to look after its customers."

Experian was down 2.4% after Morgan Stanley downgraded the credit checking agency to Equal Weight from Overweight.

In the FTSE 250, Plus500 was up 2.8%. The contract-for-difference trading provider hailed an "outstanding" operational and financial performance throughout 2021 that exceeded market expectations.

For 2021, Plus500 said revenue is estimated around USD718 million, supported by customer income - a key underlying growth metric - of USD702 million. The revenue figure is below the USD872.5 million posted in 2020, but higher than the company-compiled consensus analyst forecast of USD655.2 million.

In addition, Plus500 said that it was considering a new share buyback programme, following the completion of the USD12.6 million buyback scheme announced in October.

On AIM, Avacta was down 27% after the cancer-focused immunotherapies developer halted the sales of its AffiDX antigen test due to its lower sensitivity to detecting the Omicron variant of Covid-19.

Avacta said that the cause for the lower sensitivity of the test is the antibody with which the company Affimer is paired. As a result, Avacta has paused sales of the antigen test as it works to replace the antibody in the product to improve its performance.

The pound was quoted at USD1.3587 at midday on Monday, up from USD1.3572 at the London equities close Friday.

The euro stood at USD1.1327, lower against USD1.1343. Against the Japanese yen, the dollar was trading at JPY115.77, up from JPY115.64.

On the economic front, the unemployment rate in the eurozone continued to edge down in November. Figures released from Eurostat showed the euro area unemployment rate stood at 7.2% in November, down from 7.3% in October.

The reading, in line with market forecasts, also was down from 7.4% in November 2020 and the 7.3% reported for February 2020, the month before the pandemic began to hit Europe.

"The outlook for unemployment remains quite bright," Dutch bank ING said of the eurozone report. "Continued declines over the coming months are likely, although the re-entry of people to the labour market could slow the pace over the course of 2022. Nevertheless, this job market strength is set to feed through to wage negotiations and adds to medium-term expectations of inflation of around 2%. The ECB will take note as it considers the next steps in policy normalisation after its recent announcement of reducing asset purchases."

Brent oil was quoted at USD81.61 a barrel Monday at midday, down from USD81.99 late Friday. Gold stood at USD1,793.19 an ounce, marginally higher from USD1,791.80.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
19 Dec 2023 09:57

IN BRIEF: Avacta taps biopharma veteran as Therapeutics business chief

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Hires Simon Bennett as chief business officer of Therapeutics division. Says Bennett has over 26 years of commercial experience in the biopharma industry and has "worked with" various large and mid-sized companies like Bristol-Myers Squibb Co and Menarini Group.

Read more
13 Dec 2023 11:49

Avacta says study shows cancer treatment AVA6000 working as planned

(Alliance News) - Avacta Group PLC on Wednesday celebrated strong results from its latest cancer-targeting study, which showed the release of a chemotherapy to the tumour as intended.

Read more
13 Dec 2023 07:46

Avacta hails "encouraging" clinical data from cancer-targeting study

(Sharecast News) - Oncology drugs group Avacta has announced positive results from its lead pre|CISION programme, AVA6000, which it says has the potential to be "truly remarkable".

Read more
28 Sep 2023 11:08

IN BRIEF: Avacta loss widens on cost rise but clinical tests positive

Avacta Group PLC - Wetherby, England-based life sciences company that develops targeted oncology drugs and diagnostics - Pretax loss widens to GBP12.8 million in the six months that ended June 30 from GBP9.7 million a year before. Revenue doubles to GBP11.9 million from GBP5.5 million, but selling, general and administrative expenses near double as well, to GBP8.6 million from GBP4.7 million. Research costs are steady at GBP6.0 million. Has GBP26.0 million cash, up from GBP17.0 million a year before, though down from GBP41.8 million on December 31. Highlights success of AVA6000, a chemotherapy drug for cancer patients, in a Phase 1a clinical study. Avacta aims to complete a dose escalation safety study and provide results during the fourth quarter.

Read more
28 Sep 2023 07:57

Avacta reports higher losses in first half

(Sharecast News) - Cancer treatments and diagnostics group Avacta reported higher losses in the first half despite a doubling of revenues.

Read more
21 Sep 2023 15:48

UK earnings, trading statements calendar - next 7 days

Friday 22 September 
Ascential PLCHalf Year Results
Ergomed PLCHalf Year Results
First Tin PLCHalf Year Results
t42 IoT Tracking Solutions PLCHalf Year Results
t42 IoT Tracking Solutions PLCTrading Statement
Monday 25 September 
Alphawave IP Group PLCHalf Year Results
Devolver Digital IncHalf Year Results
Dialight PLCHalf Year Results
Getech Group PLCHalf Year Results
Ondine Biomedical IncHalf Year Results
Real Estate Investors PLCHalf Year Results
SpaceandPeople PLCHalf Year Results
Spectra Systems CorpHalf Year Results
Transense Technologies PLCFull Year Results
Venture Life Group PLCHalf Year Results
Wilmington PLCFull Year Results
Tuesday 26 September 
Alliance Pharma PLCHalf Year Results
AG Barr PLCHalf Year Results
Animalcare Group PLCHalf Year Results
Asos PLCTrading Statement
Boku IncHalf Year Results
Card Factory PLCHalf Year Results
Cambridge Cognition Holdings PLCHalf Year Results
Close Brothers Group PLCFull Year Results
Diaceutics PLCHalf Year Results
DigitalBox PLCHalf Year Results
Dillistone Group PLCHalf Year Results
EKF Diagnostics Holdings PLCHalf Year Results
Ferguson PLCFull Year Results
Finsbury Food Group PLCFull Year Results
IQGeo Group PLCHalf Year Results
Learning Technologies Group PLCHalf Year Results
LifeSafe Holdings PLCHalf Year Results
Mission Group PLCHalf Year Results
Mortgage Advice Bureau Holdings PLCHalf Year Results
NAHL Group PLCHalf Year Results
Next 15 Group PLCHalf Year Results
Newmark Security PLCFull Year Results
NIOX Group PLCHalf Year Results
Origin Enterprises PLCFull Year Results
PZ Cussons PLCFull Year Results
Safestay PLCHalf Year Results
Smiths Group PLCFull Year Results
Time Finance PLCFull Year Results
tinyBuild IncHalf Year Results
Wentworth Resources PLCHalf Year Results
Yu Group PLCHalf Year Results
Wednesday 27 September 
Amicorp FS (UK) PLCHalf Year Results
Aquila European Renewables PLCHalf Year Results
Arix Bioscience PLCHalf Year Results
Avingtrans PLCFull Year Results
Bens Creek Group PLCFull Year Results
Biome Technologies PLCHalf Year Results
BioPharma Credit PLCHalf Year Results
Chapel Down Group PLCHalf Year Results
Everyman Media Group PLCHalf Year Results
Fadel Partners IncHalf Year Results
NCC Group PLCFull Year Results
Old Mutual LtdHalf Year Results
Pantheon Infrastructure PLCHalf Year Results
Pendragon PLCFull Year Results
Plant Health Care PLCHalf Year Results
Safestyle UK PLCHalf Year Results
Saga PLCHalf Year Results
Skillcast Group PLCHalf Year Results
Surface Transforms PLCHalf Year Results
Xeros Technology Group PLCHalf Year Results
Zinc Media Group PLCHalf Year Results
Thursday 28 September 
Atlantic Lithium LtdFull Year Results
Avacta Group PLCHalf Year Results
Avation PLCFull Year Results
Celadon Pharmaceuticals PLCHalf Year Results
Ceres Power Holdings PLCHalf Year Results
Dar Global PLCHalf Year Results
eEnergy Group PLCFull Year Results
HSS Hire Group PLCHalf Year Results
Microlise Group PLCFull Year Results
Novacyt SAHalf Year Results
Phoenix Spree Deutschland LtdHalf Year Results
RBG Holdings PLCHalf Year Results
Shield Therapeutics PLCHalf Year Results
Silver Bullet Data Services Group PLCHalf Year Results
Trellus Health PLCHalf Year Results
Trinity Exploration & Production PLCHalf Year Results
XLMedia PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
20 Sep 2023 14:37

TRADING UPDATES: Capital inks contract; Lansdowne becomes cash shell

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Sep 2023 11:57

Avacta brings in clinical consultant as it hunts for permanent CMO

(Sharecast News) - Oncology-focussed life science company Avacta Group announced a new consultancy pact with Dr Christina Coughlin on Tuesday.

Read more
19 Sep 2023 13:39

Avacta upbeat on fresh data from chemotherapy trial

(Sharecast News) - Life sciences company Avacta Group announced the successful completion of its sixth dose escalation cohort in the ALS-6000-101 phase one clinical trial on Tuesday, assessing the safety and tolerability of the drug, AVA6000.

Read more
19 Sep 2023 13:36

Avacta notes "excellent" safety profile for prospective sarcoma drug

(Alliance News) - Avacta Group PLC on Tuesday said it successfully completed the sixth dose escalation of the ALS-6000-101 phase 1 clinical trial, in which its AVA6000 soft tissue sarcoma treatment demonstrated an "excellent" safety profile.

Read more
21 Jul 2023 16:00

IN BRIEF: Avacta Group issues 3.8 million shares to make repayment

Avacta Group PLC - Wetherby, England-based life sciences company developing targeted oncology drugs and diagnostics - Issues 3.8 million new shares of 10 pence each to settle quarterly principal of GBP2.6 million and interest repayment of GBP760,000. After settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by GBP2.6 million to GBP44.2 million.

Read more
21 Jun 2023 15:43

UK shareholder meetings calendar - next 7 days

Thursday 22 June 
Alphawave IP Group PLCAGM
Angling Direct PLCAGM
Anglo Asian Mining PLCAGM
boohoo Group PLCAGM
Braime Group PLCAGM
Card Factory PLCAGM
Ergomed PLCAGM
Falcon Oil & Gas LtdAGM
Futura Medical PLCAGM
Good Energy Group PLCAGM
Grand Vision Media Holdings PLCAGM
Longboat Energy PLCAGM
MaxRets Ventures PLCAGM
Pathfinder Minerals PLCAGM
RBG Holdings PLCAGM
Robinson PLCAGM
Sanderson Design Group PLCAGM
Team17 Group PLCAGM
Trellus Health PLCAGM
Whitbread PLCAGM
Friday 23 June 
Cadogan Petroleum PLCAGM
Mears Group PLCAGM
Non-Standard Finance PLCAGM
Ocean Harvest Technology Group PLCAGM
Oxford Biomedica PLCAGM
Pelatro PLCAGM
Petrofac LtdAGM
Princess Private Equity Holding LtdAGM
Rathbones Group PLCGM re agreement regarding all-share combination with Invested Wealth & Investment Ltd
Supply@Me Capital PLCGM re open offer warrant holders
Vietnam Enterprise Investments LtdAGM
VPC Specialty Lending Investments PLCAGM
Monday 26 June 
Aterian PLCAGM
Capricorn Energy PLCAGM
Corre Energy BVAGM
Facilities by ADF PLCAGM
Lexington Gold LtdSGM re proposed acquisition of White Rivers Exploration Ltd
LifeSafe Holdings PLCAGM
Premier African Minerals LtdAGM
Vast Resources PLCGM re issuing new share capital
Volvere PLCAGM
Tuesday 27 June 
Acuity RM Group PLCAGM
Comptoir Group PLCAGM
Creo Medical Group PLCAGM
First Tin PLCAGM
Forward Partners Group PLCAGM
Galantas Gold CorpAGM
Gemfields Group LtdAGM
Golden Prospect Precious Metals LtdAGM
Hamak Gold LtdAGM
ICG Enterprise Trust PLCAGM
Impellam Group PLCAGM
India Capital Growth Fund LtdAGM
Inspiration Healthcare Group PLCAGM
Instem PLCAGM
JD Sports Fashion PLCAGM
Kingfisher PLCAGM
Mercantile Ports & Logistics LtdGM re equity fundraising
Mobile Tornado Group PLCAGM
Revolution Beauty Group PLCAGM
Scottish Mortgage Investment Trust PLCAGM
Serabi Gold PLCAGM
Sondrel Holdings PLCAGM
Surface Transforms PLCAGM
Surgical Innovations Group PLCAGM
Trinity Exploration & Production PLCAGM
Wednesday 28 June 
Atalaya Mining PLCAGM
Avacta Group PLCAGM
Boku IncAGM
Cambridge Cognition Holdings PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Cobra Resources PLCAGM
Cora Gold LtdAGM
Dial Square Investments PLCAGM
Itaconix PLCAGM
NB Distressed Debt Investment Fund LtdAGM
Panthera Resources PLCGM re directors’ authority to allot shares
Phoenix Spree Deutschland LtdAGM
Pineapple Power Corp PLCAGM
Polarean Imaging PLCAGM
RA International Group PLCAGM
Schroder European Real Estate Investment Trust PLCAGM
Shield Therapeutics PLCAGM
St Mark Homes PLCAGM
Star Phoenix Group LtdAGM
ValiRx PLCAGM
Velocys PLCAGM
Vertu Motors PLCAGM
Warpaint London PLCAGM
Westminster Group PLCAGM
Zenova Group PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
21 Jun 2023 13:53

Avacta completes fifth dose escalation in chemotherapy trial

(Sharecast News) - Life sciences company Avacta announced the successful completion of the fifth dose escalation cohort in the phase 1 clinical trial for AVA6000 on Wednesday.

Read more
21 Jun 2023 09:58

Avacta says AVA6000 fifth dose escalation results "very favourable"

(Alliance News) - Avacta Group PLC on Wednesday said it has completed the fifth dose escalation cohort in its phase 1 clinical study of AVA6000.

Read more
19 Jun 2023 12:43

IN BRIEF: Avacta says no fundraising imminent after market speculation

Avacta Group PLC - Wetherby, England-based life sciences company developing targeted oncology drugs and diagnostics - Reponds to recent market speculation regarding a possible fundraising. Says no fundraising is imminent. Notes it has a strong cash balance of GBP27 million as at May 31 and expects strong new flow in the company months.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.